[{"id":"8f7947e2-9124-4105-8e09-87320d4b0bca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03205176","created_at":"2021-01-18T15:48:59.636Z","updated_at":"2024-07-02T16:36:30.672Z","phase":"Phase 1","brief_title":"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","source_id_and_acronym":"NCT03205176","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • SRA515"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 04/08/2021","study_completion_date":" 04/08/2021","last_update_posted":"2021-05-06"}]